Neurofilament light chain (NfL) is emerging as a clinically useful plasma biomarker for damage occurring in the brain, including in AD where it tracks with cortical thinning and cognitive decline [55–57], while in mouse models of AD it correlates with plaque load [38]. The gene discussed is NEFL; the disease is Alzheimer disease.